These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18835166)

  • 1. Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.
    Ishida H; Isami S; Matsumura T; Umehara H; Yamashita Y; Kajita J; Fuse E; Kiyoi H; Naoe T; Akinaga S; Shiotsu Y; Arai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5472-7. PubMed ID: 18835166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
    Gaul MD; Xu G; Kirkpatrick J; Ott H; Baumann CA
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4861-5. PubMed ID: 17611106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
    Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Omori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):456-60. PubMed ID: 22101132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
    Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
    Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
    Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
    Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity.
    Hughes TV; Xu G; Wetter SK; Connolly PJ; Emanuel SL; Karnachi P; Pollack SR; Pandey N; Adams M; Moreno-Mazza S; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4896-9. PubMed ID: 18678484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, cytostatic activity and ADME properties of C-5 substituted and N-acyclic pyrimidine derivatives.
    Kraljević TG; Klika M; Kralj M; Martin-Kleiner I; Jurmanović S; Milić A; Padovan J; Raić-Malić S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):308-12. PubMed ID: 22130132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Workman P; Waterfield MD; Parker P
    Bioorg Med Chem Lett; 2007 May; 17(9):2438-42. PubMed ID: 17339109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Hsu JT; Yeh TK; Yen SC; Chen CT; Hsieh SY; Hsu T; Lu CT; Chen CH; Chou LH; Chiu CH; Chang YI; Tseng YJ; Yen KR; Chao YS; Lin WH; Jiaang WT
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4654-9. PubMed ID: 22726931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
    Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
    Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.
    Kemnitzer W; Kuemmerle J; Zhang HZ; Kasibhatla S; Tseng B; Drewe J; Cai SX
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4410-5. PubMed ID: 19500976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
    Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
    J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
    Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
    Patel HK; Grotzfeld RM; Lai AG; Mehta SA; Milanov ZV; Chao Q; Sprankle KG; Carter TA; Velasco AM; Fabian MA; James J; Treiber DK; Lockhart DJ; Zarrinkar PP; Bhagwat SS
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5182-5. PubMed ID: 19646870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.